TBX-1400
/ Taiga Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 10, 2020
Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency
(clinicaltrials.gov)
- P1; N=8; Not yet recruiting; Sponsor: Taiga Biotechnologies, Inc.; Trial completion date: Mar 2023 ➔ Mar 2024; Trial primary completion date: Feb 2023 ➔ Feb 2024
Clinical • Trial completion date • Trial primary completion date
1 to 1
Of
1
Go to page
1